PROGESTERONE SUMMARY
Progesterone injection, a progestin, is a sterile solution of progesterone in a suitable vegetable oil available for intramuscular use. Progesterone occurs as a white or creamy white, crystalline powder. It is odorless and is stable in air. Practically insoluble in water, it is soluble in alcohol, acetone, and dioxane and sparingly soluble in vegetable oils.
This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer.
|
NEWS HIGHLIGHTSMedia Articles Related to Progesterone
SGO: Hint of Chemoprevention Potential for Lynch Syndrome (CME/CE)
Source: MedPage Today Hematology/Oncology [2010.03.16]
SAN FRANCISCO (MedPage Today) -- Oral contraceptives and medroxyprogesterone acetate (MPA, DepoProvera) may have potential as chemopreventive agents for endometrial cancer in women with Lynch syndrome, biomarker data from a small randomized trial suggest.
What Is Hormone Replacement Therapy (HRT)? What Are The Benefits And Risks Of Hormone Replacement Therapy?
Source: Endocrinology News From Medical News Today [2010.03.09]
Hormone replacement therapy, commonly known as HRT is a treatment used to replace hormones that the body is no longer producing because of the menopause. The hormones that need replacing are estrogen and progesterone. The therapy is based on the notion that the treatment may prevent discomfort caused by diminished circulating estrogen and progesterone hormones...
Published Studies Related to Progesterone
Double-blind placebo-controlled study to evaluate the effect of pro-juven progesterone cream on atherosclerosis and bone density. [2009.09]
OBJECTIVE: To establish whether treatment for three years with pro-juven progesterone cream affects progression of atherosclerotic plaques or bone density in postmenopausal women. Design Randomized double-blind placebo-controlled trial. Sample One hundred and thirty-one healthy postmenopausal women aged between 50 and 75 years with at least one asymptomatic arterial plaque visible on ultrasound of the carotid or femoral bifurcation... CONCLUSION: Pro-juven progesterone cream 20 mg twice daily did not affect progression of asymptomatic atherosclerosis or deterioration in bone density over three years.
Progesterone does not prevent preterm births in women with twins. [2009.09]
OBJECTIVE: To compare preterm birth rate and neonatal outcome in twin gestations randomized to either 17 alpha-hydroxyprogesterone caproate (17P) or placebo... CONCLUSION: Amongst this group of twin gestations weekly 17HP injections did not reduce the incidence of preterm birth or the complications associated with prematurity.
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. [2009.08.20]
PURPOSE: Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with activity in HER2-amplified metastatic breast cancer (MBC). Its role in non-HER2-amplified MBC remains unclear. EGF30001, a phase III trial of lapatinib and paclitaxel versus paclitaxel and placebo, demonstrated lapatinib does not significantly benefit HER2-negative or HER2-unselected patients with MBC. Published data support interactions between steroid hormone and peptide growth factor signaling. We hypothesized that molecular subgroups may exist within EGF30001 that would benefit from lapatinib... CONCLUSION: Although subgroups are small, these analyses support the hypothesis that semiquantitative determination of hormone receptor status may be a surrogate for EGFR and/or HER2 dependency.
Progesterone concentrations, exogenous equine chorionic gonadotropin, and timing of prostaglandin F(2alpha) treatment affect fertility in postpuberal Nelore heifers. [2009.08]
Two experiments were performed to test the hypothesis that elevated progesterone concentrations impair pregnancy rate to timed artificial insemination (TAI) in postpuberal Nelore heifers. In Experiment 1, postpuberal Nelore heifers (n=398) received 2mg estradiol benzoate (EB) and either a new progesterone-releasing intravaginal device containing 1.9g of progesterone (CIDR) (first use) or a CIDR previously used for 9 d (second use) or for 18 d (third use) on Day 0, 12.5mg prostaglandin F(2alpha) (PGF(2alpha)) on Day 7, 0.5mg estradiol cypionate (ECP) and CIDR withdrawal on Day 9, and TAI on Day 11.
Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. [2009.08]
OBJECTIVE: The aim of this study was to investigate which add-back hormone replacement therapy would be most beneficial in terms of mood effects for patients with premenstrual dysphoric disorder who are receiving gonadotropin-releasing hormone agonist therapy... CONCLUSION: Based on the findings of the present study, long-cycle add-back treatment to avoid frequent progestagen use appears to be most beneficial for patients with premenstrual dysphoric disorder.
Clinical Trials Related to Progesterone
Evaluating the Roles of Estrogen and Progesterone in Heart Metabolism [Completed]
Estrogen and progesterone are two main female sex hormones. When a woman goes through
menopause, the body's production of estrogen and progesterone significantly decreases. Recent
studies have shown that the breakdown of fatty acids in cardiac muscle is important in
maintaining a healthy heart, and that estrogen may enhance this process. Also, cardiovascular
disease (CVD) occurs more frequently in postmenopausal women than in premenopausal women.
This study will determine in postmenopausal women whether estrogen increases the heart's
ability to use fats as energy and whether progesterone decreases this effect.
Multi-Center, Randomized, Open-Label, Parallel Group Study of a Vaginal Micronized Progesterone Tablet (Endometrin®) Compared to Crinone 8% Vaginal Gel in Female Patients Undergoing In-Vitro Fertilization (IVF) [Completed]
This multicenter, randomized, open-label study will be performed in approximately 990 healthy
females undergoing IVF. Each study center will follow their study center standard practice
for IVF unless otherwise noted in this protocol. The study centers will be provided with the
medications for down regulation, stimulation and ovulation induction. The subjects will be
randomized to study medication on the day of oocyte retrieval or the day following and will
continue treatment for up to 10 weeks. The subjects with a confirmed pregnancy will be
required to return to the clinic several times during the course of the 10 week treatment
period for serum pregnancy tests and transvaginal ultrasounds to monitor the pregnancy.
Artificial Endometrial Preparation for Frozen Thawed Embryo Transfer Applying Either Endometrin or Utrogestan [Suspended]
The transfer of frozen-thawed embryos can be performed in a natural ovulatory cycle or in a
hormonally manipulated cycle with a comparable pregnancy rate of 15%-20% per ET. When a
hormonally modulated ET cycle is scheduled,an artificial endometrial preparation is carried
out using estrogen stimulation followed by a concomitant progesterone treatment. Two
progestative drugs are currently used in conventional IVF treatment, Utrogetan and
Endometrin. Although Endometrin has been be efficiently used to support the luteal phase
after embryo transfer in IVF cycles, currently, there is no study that assess its efficacy
for clinical use in frozen-thawed ET cycles. The present study aims to compare the outcome of
frozen thawed ET cycles when either Endometrin or Utrogestan are used as the progestative
substitution in an artificially prepared endometrium.
Progesterone Reduces Wakefulness in Sleep EEG and Has no Effect on Cognition in Healthy Postmenopausal Women [Completed]
Sleep is impaired in postmenopausal women (difficulty falling asleep, frequent awakenings).
Progesterone prompted benzodiazepine-like effects on sleep EEG in young normal male
subjects.
Aim of this study was to test if replacement therapy with progesterone improves sleep after
menopause.
Design, Setting, and Participants: A double blind cross-over design study with 2 treatment
intervals of 21 days duration separated by a 2 weeks washout was performed. A oral dose of
300mg micronized progesterone was given each for 21 days. At the beginning and the end of the
two intervals a sleep EEG was recorded and cognitive performance was assessed in 10 healthy
postmenopausal women (age: 54-70 yrs).
Comparison of DR-2011 to a Progesterone Vaginal Gel for Luteal Phase Replacement [Completed]
|
